Kapiglucagon
Type 1 Diabetes (for use in artificial pancreas)
Pre-clinicalActive
Key Facts
Indication
Type 1 Diabetes (for use in artificial pancreas)
Phase
Pre-clinical
Status
Active
Company
About ImmuPharma
ImmuPharma is a clinical-stage biotech focused on developing curative therapies for autoimmune diseases and innovative solutions for diabetes management. Its core technology is the P140 (Lupuzor) peptide, a first-in-class 'immunormalizer' designed to address the root cause of autoimmunity by modulating the chaperone-mediated autophagy pathway. The company is also advancing Kapiglucagon, a stable glucagon prodrug for next-generation artificial pancreas technology. With a leadership team combining scientific, clinical, and financial expertise, ImmuPharma aims to shift the treatment paradigm from symptom management to disease modification.
View full company profile